Search Results for “research” – Page 6 – media

CMT Research Foundation funds study investigating treatment for CMT1X disease

The CMT Research Foundation (CMTRF) has invested in a study being led by researchers at the University of Illinois at Chicago to investigate whether a commercially available drug could potentially treat X-linked Charcot-Marie-Tooth disease (CMT1X). The study will determine whether the drug can improve symptoms in mouse models of CMT1X. Recognised as a rare, peripheral neuropathy disease that is estimated to affect more than 2.6 million people globally, Charcot-Marie-Tooth disease (CMT) is a group of inherited conditions that damage the peripheral nerves, which are found outside the main central nervous system. Currently the second most common form of CMT, CMTX1 is caused by mutations in the gene that encodes for the connexin 32 gap junction protein. Associated with inflammation, the condition is said to contribute to the damage of the protective covering of nerve cells, which leads to disease symptoms including muscle weakness, atrophy and numbness. The study, led by ...
- Source: drugdu
- 103
- April 28, 2024
Researchers introduce new AI tool to help clinicians capture uncertainty in medical images

The Tyche model could help clinicians and researchers capture crucial information in images Researchers from the Massachusetts Institute of Technology (MIT), the Broad Institute of MIT and Harvard, and Massachusetts General Hospital have introduced a new artificial intelligence (AI) tool to capture the uncertainty in a medical image. Funded by the National Institute of Health, the Eric and Wendy Schmidt Center and Quanta Computer, the Tyche machine-learning model could help clinicians and researchers capture crucial information. In biomedicine, AI models help clinicians by highlighting pixels that show signs of a certain disease or anomaly. However, these types of models usually only provide one answer. “Having options can help in decision-making” and “so it is important to take this uncertainty into account,” said MIT computer science PhD candidate, Marianne Rakic. Researchers developed Tyche after modifying a straightforward neural network architecture. After feeding the tool a few examples of segmentation tasks, such ...
- Source: drugdu
- 70
- April 23, 2024
Francis Crick researchers reveal pathways linking intestinal inflammation and colitis

Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis The study, published in Nature Immunology, could help identify new ways to treat inflammatory bowel disease (IBD). Collectively known as IBD, Crohn’s disease and ulcerative colitis are incurable conditions that involve excessive inflammation in the gut and affect over 500,000 people in the UK, according to Crohn’s & Colitis UK. In this study, researchers deleted two proteins, c-Maf and Blimp-1, from T cells in mice to understand their role in maintaining gut health via IL-10. Mutations in the cytokine IL-10 or its receptor can result in IBD in children and it has previously been shown that c-Maf and Blimp-1 can drive the activity of the IL-10 gene in T cells. They found that, when combined with an environmental trigger – an infection with the Helicobacter hepaticus bacterium – IL-10 activity in T cells was reduced and ...
- Source: drugdu
- 82
- April 17, 2024
Nine UCL researchers secure £560m in research funding from ERC

Approximately 14% of the competition-submitted proposals were selected to receive funding Nine researchers from University College London (UCL) have secured nearly £560m in funding from the European Research Council’s (ERC) Advanced Grants to advance researchers in fields including biochemistry, nanotechnologies and regenerative medicine. Approximately 14% of the competition-submitted proposals were selected for funding, comprising 255 researchers, and could create over 2,000 new jobs. Set up in 2007 by the EU, the ERC has been funding research via the Advanced Grant to universities and research centres across 19 EU member states and associated countries, including the UK, Germany and France. The funding will be used for projects including the study of the roles of priority proteins in cellular quiescence and ageing, the thymus gland’s functions within the immune system and lung cancer. UCL professor Charles Swanton from the UCL Cancer Institute, along with UCL professor Paola Bonfanti and senior group leader ...
- Source: drugdu
- 81
- April 17, 2024
Researchers call to reduce repeat antibiotic prescriptions for respiratory tract infections

RTIs account for around 60% of global antibiotic prescribing and are a key driver of AMR Researchers from the Universities of Bristol, Bath, King’s College London and the University Medical Center Utrecht have called for a reduction in the use of repeat antibiotic prescriptions in primary care for the same respiratory tract infection (RTI) episode, based on findings from a study. Published in the Journal of Infection, the study found high rates of repeat within-episode prescriptions for RTI in primary care in England, despite evidence of little benefit. Accounting for around 60% of antibiotic prescribing in primary care globally, RTIs are caused by viruses and are one of the key drivers of antimicrobial resistance. The study analysed over 900,000 RTI episodes from clinical records across 530 English general practices. Researchers found that nearly 30% of adults and 10% of children had received a second course of antibiotics within the same ...
- Source: drugdu
- 120
- April 13, 2024
US researchers reveal positive results of personalised vaccine for liver cancer

Researchers from the Johns Hopkins Kimmel Cancer Center and its Convergence Institute have revealed promising results of a personalised vaccine for liver cancer in a clinical trial. Results from the study were published in Nature Medicine and were recently presented at the American Association for Cancer Research’s annual meeting. Recognised as the most common type of liver cancer, hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally, with fewer than one in ten patients surviving five years after diagnosis. Researchers took tumour biopsy cells from 36 HCC patients to identify cancer-associated genetic mutations in the tumour to manufacture a personalised vaccine containing DNA for selected mutated genes. Involving 36 patients living with HCC, investigators added a personalised anti-tumour vaccine to Merck & Co’s – known as MSD outside the US and Canada – PD-1 inhibitor therapy, Keytruda (pembrolizumab), a standard immunotherapy. The personalised vaccine works by ...
- Source: drugdu
- 113
- April 11, 2024
Unitaid funds over £6m to Liverpool researchers to treat major diseases

A research project led by the University of Liverpool has been awarded over £6m by Unitaid, a global health initiative to prevent, diagnose and treat major diseases in low- and middle-income countries (LMICs) and to advance long-acting therapeutics to treat or prevent tuberculosis, malaria and hepatitis C. First launched in 2020, the LONGEVITY project aims to ensure that therapeutics for these conditions are easily accessible in LMICs as part of the University of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT). To date, the project has already accomplished preclinical proof of concept for long-acting medications for tuberculosis, an infectious disease caused by a bacterium that affects the lungs, and a therapy for the hepatitis C virus, which can lead to liver infection. Caused by a parasite transmitted through bites of infected mosquitoes, malaria is responsible for an estimated 247 million cases, according to the World Health Organization’s 2022 World Malaria ...
- Source: drugdu
- 141
- April 10, 2024
Cambridge researchers begin new trial for oesophageal cancer screening

Researchers at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have announced the launch of the BEST4 trial to evaluate a capsule sponge test to prevent oesophageal cancer. Funded by Cancer Research UK and the National Institute for Health and Research, the capsule sponge could see routine screening introduced into the NHS if successful. Responsible for around 9,200 new cases every year in the UK, oesophageal cancer occurs in the long, hollow tube that runs from the throat to the stomach, known as the oesophagus. The BEST4 trial, launched at Addenbrooke’s Hospital, is investigating whether the pill-on-a-thread test can be used to screen or monitor those most at risk of the disease. The ten-minute test is used for Barrett’s oesophagus, sometimes called a pre-cancerous condition, which is usually identified via an endoscopy and a biopsy at a hospital, following a GP referral. The process is time-consuming, unpleasant ...
- Source: drugdu
- 79
- April 7, 2024
Latest Research Results of Magnesium Isoglycyrrhizinate GM-DILI-002 Announced

Recently, the 33rd Annual Meeting of the Asia-Pacific Association for the Study of the Liver (APASL 2024) presented a study (GM-DILI-002) analyzing the efficacy of Chiatai Tianqing magnesium isoglycyrrhizinate (MgIG) in the treatment of liver injury associated with a novel antitumor drug based on real-world data from China, and the results of the study (No. 100906 and No. 100910) fill the evidence-based Gap. This real-world, non-interventional, multi-center, retrospective study was conducted in three main settings. The study was based on an e-diagnostic system that screened and analyzed data from a population of 1,710 patients who met international liver biochemical criteria related to DILI (drug-induced liver injury) during treatment with novel antineoplastic agents. In recent years, the emergence of new antitumor drugs, such as molecular targeting and immune checkpoint inhibitors, has led to a continuous improvement in the survival of tumor patients, but at the same time the problem of drug-related ...
- Source: drugdu
- 202
- April 4, 2024
Researchers Present First Study Using Biomimetic AI Digital Twins

Mike Hollan The study used technology developed by a variety of companies, including RYLTI. AI digital twins are here. A group of researchers presented the first study to use digital twins created using AI. According to a press release,1 the group consisted of researchers from Genzeva, LumeGene, RYLTI, Brigham & Women’s Hospital of Harvard University, and QIAGEN Digital Insights worked together to bring the digital creations into a study on the molecular mechanisms of endometrial-related disorders. Dr. William G. Kearns, co-founder, CEO, and chief scientific officer at Genzeva and LumaGene, led the study. In a press release, he said, “This landmark study demonstrated a way to combine omics and a digital twin ecosystem to understand the molecular mechanism of disease better. By incorporating Genzeva’s multiomics platform, QIAGEN’s Digital Insight, and RYLTI’s pioneering biomimetic AI platform for genomic analyses we uncovered hidden dark data with insights that may never have been ...
- Source: drugdu
- 143
- April 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.